Ep. 164 - Viehbacher’s Vision, NK Cells & Bat Biotech

from BioCentury This Week · host BioCentury

On the latest episode of the BioCentury This Week podcast, BioCentury’s editors assess the challenges and opportunities facing Christopher Viehbacher as he begins to implement his vision for Biogen. The team also analyzes the state of play among NK cell therapy companies and discusses highlights from BioCentury’s Emerging Company Profile of Paratus Sciences Corp., a well-funded biotech being built around the idea that insights derived from the study of bat biology can be applied directly to human health and health security. This week’s podcast is sponsored by Jeito Capital.Reach us by sending a text

Episode metadata supplied by the publisher feed · Published Mar 7, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

Ep. 164 - Viehbacher’s Vision, NK Cells & Bat Biotech

0:00 26:44

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BioCentury This Week?

This episode is 26 minutes long.

When was this BioCentury This Week episode published?

This episode was published on March 7, 2023.

Can I download this BioCentury This Week episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!